Expression changes in BRCA1-deficient breast cancer PDX models treated with PARP-inhibitors.. PARP-inhibitors applied to BRCA1-null PDX models

BRCA1 deficiencies cause breast, ovarian and other cancers, and render tumours hypersensitive to PARP-inhibitors. To understand resistance mechanisms, we conducted explored expression changes in BRCA1-deficient breast cancer PDX models treated with PARP-inhibitors.